Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

EAACI statement on the pathogenesis, immunology, and immune-targeted management of the Multisystem Inflammatory Syndrome in Children (MIS-C) or Pediatric Inflammatory Multisystem Syndrome (PIMS).
  • +21
  • Wojciech Feleszko,
  • Magdalena Okarska-Napierała,
  • Emilie Pauline Buddingh,
  • Marketa Bloomfield,
  • Anna Sediva,
  • Carles Bautista-Rodriguez,
  • Helen Brough,
  • Philippe Eigenmann,
  • Thomas Eiwegger,
  • Andrzej Eljaszewicz,
  • Stefanie Eyerich,
  • Cristina Gomez-Casado,
  • Alain Fraisse,
  • Jozef Janda,
  • Rodrigo Jiménez-Saiz,
  • Tilmann Kallinich,
  • Inge Kortekaas Krohn,
  • Charlotte Mørtz,
  • CARMEN RIGGIONI,
  • Joaquin Sastre,
  • Milena Sokolowska,
  • Ziemowit Strzelczyk,
  • Eva Untersmayr,
  • Gerdien Tramper
Wojciech Feleszko
Warszawski Uniwersytet Medyczny

Corresponding Author:[email protected]

Author Profile
Magdalena Okarska-Napierała
Warszawski Uniwersytet Medyczny
Author Profile
Emilie Pauline Buddingh
Leids Universitair Medisch Centrum
Author Profile
Marketa Bloomfield
Univerzita Karlova
Author Profile
Anna Sediva
Univerzita Karlova
Author Profile
Carles Bautista-Rodriguez
Royal Brompton Hospital
Author Profile
Helen Brough
King's College London School of Life Course Sciences
Author Profile
Philippe Eigenmann
Hopitaux Universitaires Geneve
Author Profile
Thomas Eiwegger
Karl Landsteiner Privatuniversitat fur Gesundheitswissenschaften GmbH
Author Profile
Andrzej Eljaszewicz
Uniwersytet Medyczny w Bialymstoku
Author Profile
Stefanie Eyerich
Zentrum Allergie und Umwelt
Author Profile
Cristina Gomez-Casado
Heinrich-Heine-Universitat Dusseldorf Medizinische Fakultat
Author Profile
Alain Fraisse
Royal Brompton Hospital
Author Profile
Jozef Janda
Univerzita Karlova
Author Profile
Rodrigo Jiménez-Saiz
Instituto de Investigacion del Hospital de La Princesa
Author Profile
Tilmann Kallinich
Charite Universitatsmedizin Berlin
Author Profile
Inge Kortekaas Krohn
Vrije Universiteit Brussel - Brussels Health Campus
Author Profile
Charlotte Mørtz
Odense Universitetshospital
Author Profile
CARMEN RIGGIONI
National University of Singapore Yong Loo Lin School of Medicine
Author Profile
Joaquin Sastre
Instituto de Salud Carlos III
Author Profile
Milena Sokolowska
Universitat Zurich Schweizerisches Institut fur Allergie- und Asthmaforschung
Author Profile
Ziemowit Strzelczyk
Warszawski Uniwersytet Medyczny
Author Profile
Eva Untersmayr
Medizinische Universitat Wien
Author Profile
Gerdien Tramper
Franciscus Gasthuis & Vlietland Willemsplein
Author Profile

Abstract

Multisystem inflammatory syndrome in children (MIS-C) is a rare, but severe complication of coronavirus disease 2019 (COVID-19). It develops approximately four weeks after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and involves hyperinflammation with multisystem injury, commonly progressing to shock. The exact pathomechanism of MIS-C is not known, but immunological dysregulation leading to cytokine storm plays a central role. In response to the emergence of MIS-C, the European Academy of Allergy and Clinical Immunology (EAACI) established a task force (TF) within the Immunology Section in May 2021. With the use of an online Delphi process, TF formulated clinical statements regarding immunological background of MIS-C, diagnosis, treatment, follow-up, and the role of COVID-19 vaccinations. MIS-C case definition is broad, and diagnosis is made based on clinical presentation. The immunological mechanism leading to MIS-C is unclear and depends on activating multiple pathways leading to hyperinflammation. Current management of MIS-C relies on supportive care in combination with immunosuppressive and/or immunomodulatory agents. The most frequently used agents are systemic steroids and intravenous immunoglobulin. Despite good overall short-term outcome, MIS-C patients should be followed-up at regular intervals after discharge, focusing on cardiac disease, organ damage, and inflammatory activity. COVID-19 vaccination is a safe and effective measure to prevent MIS-C. In anticipation of further research, we propose a convenient and clinically practical algorithm for managing MIS-C developed by the Immunology Section of the EAACI.
05 Dec 2022Submitted to Pediatric Allergy and Immunology
05 Dec 2022Submission Checks Completed
05 Dec 2022Assigned to Editor
05 Dec 2022Review(s) Completed, Editorial Evaluation Pending
05 Dec 2022Editorial Decision: Accept